Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XENON ILD: 129Xe MRI to Evaluate aNtifibrotic respOnse and progressioN in ILD

NCT05241275 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT05241275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05241275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XENON ILD: 129Xe MRI to Evaluate aNtifibrotic respOnse and progressioN in ILD
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 19, 2022
Completion date
August 31, 2026
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis, progressive pulmonary fibrosis